163 related articles for article (PubMed ID: 34865071)
1. Impact of Dapivirine and Placebo Vaginal Rings on the Microbiota of Adolescent, Lactating, and Postmenopausal Females.
Austin MN; Meyn LA; Avolia HA; Petrina MA; Cosentino LA; Alphonse C; Chen BA; Bunge K; Noguchi L; Beigi R; Squires K; Hillier SL
J Infect Dis; 2022 Jun; 225(12):2208-2218. PubMed ID: 34865071
[TBL] [Abstract][Full Text] [Related]
2. Influence of dapivirine vaginal ring use on cervicovaginal immunity and functional microbiome in adolescent girls.
Farr Zuend C; Noël-Romas L; Hoger S; McCorriser S; Westmacott G; Marrazzo J; Hillier SL; Dezzutti C; Squires K; Bunge KE; Burgener A
AIDS; 2021 Mar; 35(3):369-380. PubMed ID: 33181534
[TBL] [Abstract][Full Text] [Related]
3. Impact of contraceptive initiation on vaginal microbiota.
Achilles SL; Austin MN; Meyn LA; Mhlanga F; Chirenje ZM; Hillier SL
Am J Obstet Gynecol; 2018 Jun; 218(6):622.e1-622.e10. PubMed ID: 29505773
[TBL] [Abstract][Full Text] [Related]
4. Greater dapivirine release from the dapivirine vaginal ring is correlated with lower risk of HIV-1 acquisition: a secondary analysis from a randomized, placebo-controlled trial.
Brown ER; Hendrix CW; van der Straten A; Kiweewa FM; Mgodi NM; Palanee-Philips T; Marzinke MA; Bekker LG; Soto-Torres L; Hillier SL; Baeten JM;
J Int AIDS Soc; 2020 Nov; 23(11):e25634. PubMed ID: 33206462
[TBL] [Abstract][Full Text] [Related]
5. Brief Report: Phase IIa Safety Study of a Vaginal Ring Containing Dapivirine in Adolescent Young Women.
Bunge KE; Levy L; Szydlo DW; Zhang J; Gaur AH; Reirden D; Mayer KH; Futterman D; Hoesley C; Hillier SL; Marzinke MA; Hendrix CW; Gorbach PM; Wilson CM; Soto-Torres L; Kapogiannis B; Nel A; Squires KE;
J Acquir Immune Defic Syndr; 2020 Feb; 83(2):135-139. PubMed ID: 31929401
[TBL] [Abstract][Full Text] [Related]
6. Safety, Acceptability and Adherence of Dapivirine Vaginal Ring in a Microbicide Clinical Trial Conducted in Multiple Countries in Sub-Saharan Africa.
Nel A; Bekker LG; Bukusi E; Hellstrӧm E; Kotze P; Louw C; Martinson F; Masenga G; Montgomery E; Ndaba N; van der Straten A; van Niekerk N; Woodsong C
PLoS One; 2016; 11(3):e0147743. PubMed ID: 26963505
[TBL] [Abstract][Full Text] [Related]
7. Phase 2a Safety, Pharmacokinetics, and Acceptability of Dapivirine Vaginal Rings in US Postmenopausal Women.
Chen BA; Zhang J; Gundacker HM; Hendrix CW; Hoesley CJ; Salata RA; Dezzutti CS; van der Straten A; Hall WB; Jacobson CE; Johnson S; McGowan I; Nel AM; Soto-Torres L; Marzinke MA;
Clin Infect Dis; 2019 Mar; 68(7):1144-1151. PubMed ID: 30289485
[TBL] [Abstract][Full Text] [Related]
8. Use of the dapivirine vaginal ring and effect on cervical cytology abnormalities.
Reddy K; Kelly C; Brown ER; Jeenarain N; Naidoo L; Siva S; Bekker LG; Nair G; Makanani B; Chinula L; Mgodi N; Chirenje Z; Kiweewa FM; Marrazzo J; Bunge K; Soto-Torres L; Piper J; Baeten JM; Palanee-Phillips T;
AIDS; 2020 Mar; 34(4):559-567. PubMed ID: 31764068
[TBL] [Abstract][Full Text] [Related]
9. Associations between the vaginal microbiome and Candida colonization in women of reproductive age.
Tortelli BA; Lewis WG; Allsworth JE; Member-Meneh N; Foster LR; Reno HE; Peipert JF; Fay JC; Lewis AL
Am J Obstet Gynecol; 2020 May; 222(5):471.e1-471.e9. PubMed ID: 31654610
[TBL] [Abstract][Full Text] [Related]
10. Clinical and Virologic Outcomes Following Initiation of Antiretroviral Therapy Among Seroconverters in the Microbicide Trials Network-020 Phase III Trial of the Dapivirine Vaginal Ring.
Riddler SA; Balkus JE; Parikh UM; Mellors JW; Akello C; Dadabhai S; Mhlanga F; Ramjee G; Mayo AJ; Livant E; Heaps AL; O'Rourke C; Baeten JM;
Clin Infect Dis; 2019 Jul; 69(3):523-529. PubMed ID: 30346511
[TBL] [Abstract][Full Text] [Related]
11. Assessing Per-Sex-Act HIV-1 Risk Reduction Among Women Using the Dapivirine Vaginal Ring.
Stalter RM; Dong TQ; Hendrix CW; Palanee-Phillips T; van der Straten A; Hillier SL; Kiweewa FM; Mgodi NM; Marzinke MA; Bekker LG; Soto-Torres L; Baeten JM; Brown ER;
J Infect Dis; 2024 Apr; 229(4):1158-1165. PubMed ID: 38099506
[TBL] [Abstract][Full Text] [Related]
12. A safety and pharmacokinetic trial assessing delivery of dapivirine from a vaginal ring in healthy women.
Nel A; Haazen W; Nuttall J; Romano J; Rosenberg Z; van Niekerk N
AIDS; 2014 Jun; 28(10):1479-87. PubMed ID: 24901365
[TBL] [Abstract][Full Text] [Related]
13. Pre-clinical development of a combination microbicide vaginal ring containing dapivirine and darunavir.
Murphy DJ; Desjardins D; Dereuddre-Bosquet N; Brochard P; Perrot L; Pruvost A; Le Grand R; Lagatie O; Vanhooren L; Feyaerts M; van Roey J; Malcolm RK
J Antimicrob Chemother; 2014 Sep; 69(9):2477-88. PubMed ID: 24862093
[TBL] [Abstract][Full Text] [Related]
14. Contraceptive rings promote vaginal lactobacilli in a high bacterial vaginosis prevalence population: A randomised, open-label longitudinal study in Rwandan women.
Crucitti T; Hardy L; van de Wijgert J; Agaba S; Buyze J; Kestelyn E; Delvaux T; Mwambarangwe L; De Baetselier I; Jespers V;
PLoS One; 2018; 13(7):e0201003. PubMed ID: 30036385
[TBL] [Abstract][Full Text] [Related]
15. Correlates of Adherence to the Dapivirine Vaginal Ring for HIV-1 Prevention.
Husnik MJ; Brown ER; Dadabhai SS; Gaffoor Z; Jeenarain N; Kiweewa FM; Livant E; Mansoor LE; Mirembe BG; Palanee-Phillips T; Singh D; Siva S; Soto-Torres L; van der Straten A; Baeten JM;
AIDS Behav; 2021 Sep; 25(9):2801-2814. PubMed ID: 34117592
[TBL] [Abstract][Full Text] [Related]
16. Effects of a One Year Reusable Contraceptive Vaginal Ring on Vaginal Microflora and the Risk of Vaginal Infection: An Open-Label Prospective Evaluation.
Huang Y; Merkatz RB; Hillier SL; Roberts K; Blithe DL; Sitruk-Ware R; Creinin MD
PLoS One; 2015; 10(8):e0134460. PubMed ID: 26267119
[TBL] [Abstract][Full Text] [Related]
17. The significance of Lactobacillus crispatus and L. vaginalis for vaginal health and the negative effect of recent sex: a cross-sectional descriptive study across groups of African women.
Jespers V; van de Wijgert J; Cools P; Verhelst R; Verstraelen H; Delany-Moretlwe S; Mwaura M; Ndayisaba GF; Mandaliya K; Menten J; Hardy L; Crucitti T;
BMC Infect Dis; 2015 Mar; 15():115. PubMed ID: 25879811
[TBL] [Abstract][Full Text] [Related]
18. Characterization of Viruses in Phase 3 and Phase 3b Trials (the Ring Study and the Dapivirine Ring Extended Access and Monitoring Trial) of the Dapivirine Vaginal Ring for Human Immunodeficiency Virus Type 1 Infection Risk Reduction.
Steytler J; Craig C; van der Ryst E; Van Baelen B; Nuttall J; van Niekerk N; Mellors J; Parikh U; Wallis C;
Clin Infect Dis; 2023 Mar; 76(6):996-1002. PubMed ID: 36345569
[TBL] [Abstract][Full Text] [Related]
19. Acceptability of the Dapivirine Vaginal Ring in Postmenopausal US Women.
Shapley-Quinn MK; Laborde N; Luecke E; Hoesley C; Salata RA; Johnson S; Nel A; Soto-Torres L; Chen BA; van der Straten A
AIDS Patient Care STDS; 2022 Mar; 36(3):97-105. PubMed ID: 35289688
[TBL] [Abstract][Full Text] [Related]
20. Safety and Efficacy of a Dapivirine Vaginal Ring for HIV Prevention in Women.
Nel A; van Niekerk N; Kapiga S; Bekker LG; Gama C; Gill K; Kamali A; Kotze P; Louw C; Mabude Z; Miti N; Kusemererwa S; Tempelman H; Carstens H; Devlin B; Isaacs M; Malherbe M; Mans W; Nuttall J; Russell M; Ntshele S; Smit M; Solai L; Spence P; Steytler J; Windle K; Borremans M; Resseler S; Van Roey J; Parys W; Vangeneugden T; Van Baelen B; Rosenberg Z;
N Engl J Med; 2016 Dec; 375(22):2133-2143. PubMed ID: 27959766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
